Representative Kim Schrier (D-WA) has been named the Democratic co-chair of the Congressional Diabetes Caucus, the Endocrine Society reported on October 13, 2026. The new role becomes effective when the next Congress convenes in January 2027. Schrier will replace Representative Diana DeGette (D-CO), who lost re-election earlier this year. The Society credited DeGette with leadership on diabetes issues during her time in Congress and expressed appreciation for her work.
This appointment shifts one half of the caucus leadership. Representative Gus Bilirakis (R-FL) will continue in his role as the Republican co-chair, the Society noted. That continuity preserves the bipartisan structure of the caucus while introducing a new Democratic voice for the upcoming congressional term.
Schrier brings a distinct clinical profile to the caucus leadership. She is the only practicing pediatrician in Congress. She is also the only member of the House living with type 1 diabetes; she was diagnosed at age 16, the article stated. Those two facts framed the Society’s comments about expected contributions to legislation addressing prevention, research, and treatment for diabetes.
Her clinical training and personal experience with diabetes create a perspective that combines patient experience with medical practice. The source did not provide further detail about Schrier’s specific clinical practice, her legislative priorities beyond those listed by the Society, or any proposed bills she intends to sponsor as co-chair. Those specifics have not been reported in the source.
With Bilirakis remaining in place, the caucus preserves bipartisan leadership into the 2027 session. The Endocrine Society described the relationship between the Society and the caucus as longstanding, and emphasized ongoing collaboration. The source noted that the Society works closely with caucus co-chairs on a wide range of issues that affect endocrinologists and patients living with diabetes.
The article did not list a formal caucus agenda or enumerate planned hearings, markups, or legislative timetables tied to the leadership change. It also did not provide vote counts or internal caucus membership changes. Those operational details will need to come from caucus communications or congressional records after the new Congress convenes.
The Endocrine Society identified several policy areas it expects to pursue with the caucus under Schrier’s co-leadership. These include efforts on insulin affordability and sustained funding for the Special Diabetes Program. The Society expressed a forward-looking intent to collaborate with Schrier on measures intended to improve prevention, increase research support, and enhance treatment for people living with diabetes.
The Society’s statement was descriptive rather than prescriptive; it did not specify legislative text, funding levels, or timelines for the Special Diabetes Program or insulin cost interventions. Nor did the article report any immediate actions or formal joint initiatives scheduled for the period before Congress convenes.
Several concrete questions remain as Schrier prepares to assume the co-chair role. How will the caucus operationalize affordability measures for insulin—through price caps, expanded subsidies, procurement changes, or other mechanisms? What funding level will the caucus request or seek for the Special Diabetes Program, and over what timeframe? Which specific prevention and research priorities will be elevated in committee work and appropriations negotiations?
The Endocrine Society’s announcement framed these priorities but did not provide answers. The source did not report on Schrier’s legislative agenda, specific policy proposals, or planned collaborations with particular committees. Those are unresolved items that clinicians, researchers, and patient advocates will watch as the 2027 Congress organizes its committees and publishes its early agendas.
The change in caucus leadership places an experienced clinician and a person living with type 1 diabetes in a visible legislative role. The practical impact on insulin affordability, Special Diabetes Program funding, and research priorities will depend on the caucus’s forthcoming proposals and congressional action—none of which were detailed in the source. That absence of concrete policy detail defines the immediate next steps: public caucus statements, bill filings, and committee scheduling that will reveal how the priorities named by the Endocrine Society translate into legislation.